Form 4: Lexeo Therapeutics Officer Acquires Shares Through Employee Stock Purchase Plan

Jose Manuel Otero, Chief Technical Officer of Lexeo Therapeutics, reports acquiring 5,720 shares of common stock through the company's Employee Stock Purchase Plan.

Summary

• Jose Manuel Otero, the Chief Technical Officer of Lexeo Therapeutics, Inc. (LXEO), filed a Form 4 on April 09, 2025.
• The report details a transaction on March 14, 2025, where Otero acquired 5,720 shares of Lexeo Therapeutics' common stock through the company's 2023 Employee Stock Purchase Plan at a price of $2.61 per share.
• Following the transaction, Otero beneficially owns 63,220 shares, including 57,500 restricted stock units.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of an insider transaction. The acquisition of shares by an officer is generally viewed as a positive sign, but it's not a major event.

Positives

• The acquisition of shares by a company officer can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure of insider trading activity, which is common in publicly traded companies. It provides transparency into the actions of company executives and their confidence in the company's stock.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

Lexeo Therapeutics, LXEO, Form 4, Insider Trading, Employee Stock Purchase Plan, Stock Acquisition, Beneficial Ownership, Otero, Chief Technical Officer